Syrios Ioannis Medical Oncologist
Education & Academic Qualifications
- Medical License Medical School, University of Athens, Greece 2003
- Specialty in Medical Oncology 2013
- Fellowship in Gynecological Cancer 2014
- PhD Diploma Medical School, University of Athens, Greece 2012
- MSc on Management of health care units Hellenic Open University 2016
- ESMO Examination Certificate European Society of Medical Oncology 2012
- Diploma of the Hellenic Boards of Oncology Hellenic Society of Medical Oncology 2012
DNA ploidy and other factors affecting overall survival in patients with advanced gastric adenocarcinoma¨ Medical School, University of Athens, Greece 05.2007- 06.2012
Fellowship in Societies, Membership in Journal Editorial Committees
G.Y.ON (Young Medical Oncologists Working Group)
General Medical Council –Specialist registration (από 16/05/2013)
Hellenic Society of Medical Oncology (HESMO), Greek Cancer Society
Hellenic Cooperative Oncology Group (HeCOG)
Hellenic Oncology Research Group (HORG)
Fertility Preservation in Cancer Patients (GONEAS)
Editorial Board Member in “Journal of Balkan Union of Oncology”
AD-HOC REVIEWER for peer-reviewed international journals: “Annals of Oncology”, “Br J Surg”, “AJPP”
01.02.2016 – today Medical Oncologist YGEIA & MITERA Hospital
30.01.2014 – 30.01.2016 Consultant Medical Oncologist, 2nd Department of Medical Oncology, “Saint Savvas” Cancer Hospital, Athens, Greece
08.07.2013 – 08.01.2014 Clinical Research Fellow in Gynae/Oncology, The Royal Marsden NHS Foundation Trust, London, United Kingdom
29.03.2013 – 29.05.2013 Medical Oncologist, 1st Department of Medical Oncology, Metaxa Cancer Hospital, Piraeus, Greece
29.03.2009 – 29.03.2013 Resident Doctor in Medical Oncology, 1st Department of Medical Oncology, Metaxa Cancer Hospital, Piraeus, Greece
06.2008-12.2008 Resident Doctor in Hematology, Department of Pathophysiology, Medical School, University of Athens, Greece
06.2006-06.2008 Resident Doctor in Internal Medicine, 1st Department of Internal Medicine, Asclepeion General Hospital, Athens, Greece
12.2005-03.2010 Research associate Doctor in Medical Oncology, Department of Pathophysiology, Medical School, University of Athens, Greece
12.2004-08.2005 Compulsory military service as a Sergeant Doctor, Hellenic Army, Air Force
08.2003-08.2004 Rural Doctor at the Health Center of Dimitsana, Arkadia, Greece
05.2004-08.2004 Rural Doctor at the General Regional Hospital of Tripolis, Greece
Tutor in the Hellenic Boards of Oncology 2014
Professor of Medical Anatomy and Physiology in Medical Imaging Devices Faculty, Public Institute of Professional Training, Markopoulo, Attiki, Greece 2005–2006
Clinical & Research Interest
Gynecological Oncology & Breast Cancer
High dose chemotherapy with autologous stem cell support in solid tumors
Fertility preservation in cancer patients
Phase I-II-III Clinical trials in Gynecological Oncology, PARP and immune checkpoint inhibitors in epithelial Ovarian Cancer, Anti-angiogenesis in gynecological tumors.
Leader member in Gynaecological Oncology Research Group in the Hellenic Oncology Research Group (HORG) and Hellenic Cooperative Oncology Group (HeCOG)
Honors & Awards
Prize for the best oral presentation “Cardiotoxicity of fluoropyrimidines in different schedules of administration: a prospective study” 7th Congress of Balkan Union of Oncology, Kusadasi, Turkey, 15-19 October 2008
Scholarship granted by the Hellenic Society of Medical Oncology (HeSMO), 2013
Scholarship granted by the European School of Oncology (ESO), 2013
“Gastric Cancer: From Staging to Surgical Treatment. Procedures, Complications and Oncological Results” NOVA publishers ISBN: 978-1-62081-294-5 Chapter 3: Surgical Treatment of Early and Advanced Disease and Prognostic Factors
¨CRITICAL CARE AND EMERGENCY MEDICINE: MONITORING¨ Pashalidis Editions, Athens 2009 Lung Cancer Monitoring Chapter
Mucinous cystadenocarcinoma of the breast: the challenge of diagnosing a rare entity. Rare Tumors. 2017 Oct 3;9(3):7016
An ovarian mature cystic teratoma evolving in squamous cell carcinoma: A case report and review of the literature. Gynecol Oncol Rep. 2016 Dec 18;19:27-30
Distinct patterns of angiogenic factor expression as a predictive factor of response to chemotherapy in stage IIIA non small cell lung cancer patients. Mol Clin Oncol. 2016 Oct;5(4):440-446.
Nintedanib in combination with docetaxel for second-line treatment of advanced non-small-cell lung cancer. Expert Rev Anticancer Ther. 2015 Aug;15(8):875-84.
Thymic carcinoma: what after disease progression? J BUON 2014; 19(2): 577-584.
Advances in thymic carcinoma diagnosis and treatment: a review of literature. Med Oncol. 2014 Jul;31(7):44.
Advanced Epithelial Ovarian Cancer: From Standard Chemotherapy to Promising Molecular Pathway Targets – Where Are we Now? Anticancer Res. 2014 May;34(5):2069-77.
Treatment of patients with metastatic renal cell carcinoma undergoing hemodialysis: case report of two patients and short literature review. BMC Nephrol. 2013 Apr 12;14(1):84.
DNA ploidy: a prognostic factor of response to chemotherapy and survival in metastatic gastric adenocarcinoma. Anticancer Res. 2013 Mar;33(3):1209-1214
Cutaneous metastasis from hepatocellular carcinoma. J BUON. 2012 Oct;17(4):797-798.